Search
Cemivameran
go.drugbank.com/drugs/DB19415ApprovedIt is the active ingredient in the 2024-2025 formulation of Pfizer-BioNTech's Comirnaty vaccine.[L36030]
Cyclopentamine
go.drugbank.com/drugs/DB08999ApprovedWithdrawnIt has been widely discontinued due to the safety, effectiveness, and availability of a similar drug, propylhexedrine.
Salsalate
go.drugbank.com/drugs/DB01399ApprovedInvestigationalSalicylic acid (the active metabolite) biotransformation is saturated at anti-inflammatory doses of salsalate. … Salsalate is readily soluble in the small intestine where it is partially hydrolyzed to two molecules of salicylic acid.
Afimoxifene
go.drugbank.com/drugs/DB04468InvestigationalIt is being developed by Ascent Therapeutics.
CX-717
go.drugbank.com/drugs/DB05047IllicitInvestigationalCX-717 is an ampakine compound previously investigated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) and Alzheimer's disease.
Darolutamide
go.drugbank.com/drugs/DB12941ApprovedInvestigationalDarolutamide is a nonsteroidal androgen receptor antagonist for the treatment of castrate-resistant, non-metastatic prostate cancer (nmCRPC). This condition occurs in the majority of patients with advanced prostate cancer who have been t...
Cinoxacin
go.drugbank.com/drugs/DB00827ApprovedWithdrawnSynthetic antimicrobial related to oxolinic acid and nalidixic acid and used in urinary tract infections.
Patiromer
go.drugbank.com/drugs/DB09263ApprovedInvestigationalPatiromer is a powder for suspension in water for oral administration, approved in the U.S. as Veltassa in October, 2015. Patiromer is supplied as patiromer sorbitex calcium which consists of the active moiety, patiromer, a non-absorbed ...
ARCoV
go.drugbank.com/drugs/DB15855ExperimentalManufactured as a liquid, ARCoV is thermostable at room temperature for at least 1 week. … As of July 2020, the vaccine candidate is set for Phase 1 clinical trials to investigate for safety, tolerance, and immunogenicity (ChiCTR2000034112).
Cromoglicic acid
go.drugbank.com/drugs/DB01003ApprovedInvestigationalIt is used in the prophylactic treatment of both allergic and exercise-induced asthma, but does not affect an established asthmatic attack.
Products: GLICAT® 40 MG/ML, CROMABAK EYE DROPS 20 mg/ml